Chemotherapy (platinum and pemetrexed) in combination with erlotinib in non‐small cell lung cancer induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03‐2013 study. (15th June 2016)

• Record Type: Journal Article
• Authors: Sassier, M.; Peyro‐Saint‐Paul, L.; Clarisse, B.; Leconte, A.; Coquerel, A.; Alexandre, J.; Fedrizzi, S.; Leroy‐Terquem, E.; Madroszyk, A.; Gervais, R.
• Is Part Of: Journal of clinical pharmacy and therapeutics. Volume 41:Number 4(2016:Aug.)
• Page Start: 447
• Page End: 448
• Publication Date: 2016-06-15
• Subjects: chemotherapy -- erlotinib -- gastrointestinal toxicity -- non‐small cell lung cancer; Clinical pharmacology -- Periodicals; Chemotherapy -- Periodicals; 615
• DOI: 10.1111/jcpt.12406
• Languages: English
• ISSNs: 0269-4727

Abstract

Summary: What is known and objective: A randomized phase III study was designed to assess the efficacy and safety of second‐line platinum‐based chemotherapy with or without erlotinib in non‐small cell lung cancer (NSCLC) with EGFR‐activating mutation after secondary resistance to EGFR‐TKIs (epidermal growth factor receptor tyrosine kinase inhibitors). Case summary: We report herein two of the first three patients who presented with major gastrointestinal toxicities in the experimental arm of the trial. What is new and conclusion: Pending further data, it would seem safer to administer EGFR‐TKIs and chemotherapy sequentially rather than concomitantly. Abstract : Chronology of the events about two cases of gastrointestinal toxicity following concurrent administration of erlotinib and platinum‐based chemotherapy.